Medytox Obtains Albanian Product Approval for Two Types of Hyaluronic Acid Filler "Neuramis"
"Continuing to Expand Overseas Sales Channels...
Aiming to Increase Global Market Share"
On December 1, Medytox, a biopharmaceutical company, announced that it has obtained product approval for two types of its hyaluronic acid filler "Neuramis" from the National Agency for Medicines and Medical Devices of Albania (AKBPM).
Albania is a major emerging country in Eastern Europe. As national income and the proportion of urban population increase, the skin aesthetics and anti-aging markets are steadily growing. Medytox plans to further strengthen its expansion in Europe by successfully launching "Neuramis Deep Lidocaine" and "Neuramis Volume Lidocaine" in Albania, a market with high potential.
"Neuramis" is a hyaluronic acid filler independently developed by Medytox and has proven its product quality through CE certification from the European Union. The company has been accelerating its entry into Europe, having obtained product approval in Serbia in February this year.
A Medytox representative said, "We will accelerate our entry into the Albanian market by leveraging marketing expertise accumulated in Europe," adding, "We will continue to develop overseas sales channels to further increase our global market share."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Meanwhile, since its launch, "Neuramis" has demonstrated its efficacy and safety through over a decade of clinical data. By improving the efficiency of the hyaluronic acid cross-linking reaction, the product's longevity has been enhanced, and by minimizing the residual amount of cross-linker (BDDE), the risk of side effects such as swelling and inflammation has also been reduced. Currently, Medytox has established its presence in the global market by entering 35 countries across Europe, the Middle East, South America, and Asia.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.